NIH Halts Hydroxychloroquine Trial After Finding No Benefit for COVID-19 Patients

Reporter

6/20/2020|Updated: 6/23/2020

The National Institutes of Health (NIH) has halted a clinical trial to study the “safety and effectiveness” of hydroxychloroquine for treating the CCP virus in adults.

In a statement on June 20, the NIH said the “study shows treatment does no harm, but provides no benefit.”

Venus Upadhayaya

Reporter

Venus Upadhayaya reports on India, China, and the Global South. Her traditional area of expertise is in Indian and South Asian geopolitics. Community media, sustainable development, and leadership remain her other areas of interest.

Author’s Selected Articles

China’s Footprint Is Clear in Kashmir Crisis, Analysts Say

Taiwan’s Tougher China Stance Should Bolster Support From Other Nations: Experts

On the Brink of a Multipolar World, India’s Grand Strategy Is Largely Defined by China, Analysts Say

CCP–Cook Islands Deal Raises Concerns for New Zealand, US, Australia